Under terms of the research agreement, Kyowa Hakko Kirin will fund several glycanbiomarker and other discovery projects, with an option for further research and development. Other details of the agreement were not disclosed.
“We look forward to putting our unique glycan-analysis capabilities to the service of the specific research interests of Kyowa Hakko Kirin,” said Hidehisa Asada, Ph.D., Vice President, Research & Development of Ezose. “As the structure of our collaboration anticipates, the research will seek new discoveries that enable novel therapeutic strategies and sustain the flow of new products to market.”
Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells. The particular glycans involved may crucially determine the function of the resulting glycoprotein and its role in health and disease.
Glycomics is a natural complement to genomics and proteomics, but it has traditionally been hindered by the lack of practical high-throughput and quantitative technologies. Ezose’s proprietary GlycanMap® platform addresses this need by combining, in an automated 96-well format, high-throughput glycan enrichment with specialized MALDITOF mass spectrometry and custom bioinformatics to both structurally identify and quantitate glycans present in complex biological samples. Such glycans can serve as novel biomarkers to aid in the development of drugs, vaccines, and diagnostic tests, including companion diagnostics. In addition, glycomics holds potential for uncovering new therapeutic targets and mechanisms and for guiding the development and manufacture of glycosylated biologics and biosimilars.